Match!
Jonathan Kay
University of Massachusetts Medical School
Physical therapyRheumatoid arthritisNephrogenic systemic fibrosisDiabetes mellitusMedicine
209Publications
41H-index
9,252Citations
What is this?
Publications 215
Newest
#1Joshua F. Baker (UPenn: University of Pennsylvania)H-Index: 24
#2Charles E. Leonard (UPenn: University of Pennsylvania)H-Index: 21
Last. Jonathan Kay (UMMS: University of Massachusetts Medical School)H-Index: 41
view all 6 authors...
OBJECTIVE: To compare uptake in the ordering of biosimilars at a Veterans' Affairs medical center (VAMC) to that at an academic medical center, where institutional incentives for infused medications differ. METHODS: We performed a cross-sectional study of medical record data and estimated institutional financial incentives at two medical centers in Philadelphia: 1) the University of Pennsylvania Health System (UPHS) and 2) the local VAMC. All ordering events for filgrastim or infliximab products...
Source
#1Jonathan Kay (UMMS: University of Massachusetts Medical School)H-Index: 41
#2Thomas Dörner (Charité)H-Index: 57
Last. Ferdinand C. Breedveld (LUMC: Leiden University Medical Center)H-Index: 61
view all 5 authors...
In their correspondence, Cantini and Benucci1 voice concern regarding the recommendation of our international multidisciplinary task force on biosimilars that ‘a single switch from a bio-originator to one of its biosimilars is safe and effective.’2 This recommendation was based on consistent evidence from randomised controlled trials comparing biosimilars to their respective reference products in patients with rheumatologic diseases, in which subjects treated with a reference product were subseq...
2 CitationsSource
#1Shao-Hsien Liu (UMMS: University of Massachusetts Medical School)H-Index: 6
#1S.hao-Hsien Liu (UMMS: University of Massachusetts Medical School)
Last. Jonathan Kay (UMMS: University of Massachusetts Medical School)H-Index: 41
view all 4 authors...
Abstract Objective To review systematically and synthesize qualitatively the literature about physical activity and perceptions and attitudes towards physical activity/exercise among patients with spondyloarthritis (SpA). Methods PubMed, CINAHL and Scopus and reference lists were searched for quantitative and qualitative studies reporting on beliefs towards exercise in patients with SpA. Searches were limited to studies published from January 2000 through December 2018. The PRISMA guidelines wer...
Source
#1Raj Sengupta (Royal National Hospital for Rheumatic Diseases)H-Index: 9
#2Lianne S. Gensler (UCSF: University of California, San Francisco)H-Index: 17
Last. Atul Deodhar (OHSU: Oregon Health & Science University)H-Index: 22
view all 10 authors...
Source
#1Karl Gaffney (Norfolk and Norwich University Hospitals NHS Foundation Trust)H-Index: 3
#2Atul Deodhar (OHSU: Oregon Health & Science University)H-Index: 22
Last. Lars Bauer (UCB)H-Index: 9
view all 14 authors...
Source
#1Jonathan Kay (UMMS: University of Massachusetts Medical School)H-Index: 41
The availability of biosimilars to treat inflammatory diseases has generated concern about changing patients from a bio-originator to its biosimilar to save costs. Studies published in 2019 support the effectiveness and safety of ‘nonmedical switching’ and highlight the benefits of communicating information about biosimilars to patients in a positive light.
Source
#1Jeffrey R. Curtis (UAB: University of Alabama at Birmingham)H-Index: 61
#2Fenglong Xie (UAB: University of Alabama at Birmingham)H-Index: 25
Last. Joel D. Kallich (MCPHS University)H-Index: 2
view all 4 authors...
Biosimilar infliximab has the potential for appreciable cost savings compared to its reference biologic, but dose escalation is common and increases costs. We compared frequency of dose escalation and associated Medicare-approved amount so as to determine the break-even point at which infliximab dose escalation would offset the cost savings of using a biosimilar, referent to alternatively using golimumab. We studied Medicare enrollees with rheumatoid arthritis (RA) initiating infliximab or golim...
Source
#1Karen Salomon-Escoto (UMMS: University of Massachusetts Medical School)H-Index: 5
#2Jonathan Kay (UMMS: University of Massachusetts Medical School)H-Index: 41
Source
Source
Source
12345678910